At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
Publication|Articles|June 18, 2026
Pharmacy Practice in Focus: Oncology
- June 2026
- Volume 8
- Issue 4
Administration of Tivozanib via Gastrostomy Tube: A Pharmacokinetic Analysis
Fact checked by: Kirsty Mackay
This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.
Advertisement
Advertisement
Tivozanib is an oral multikinase inhibitor targeting VEGFR-1,-2, and 3; c-KIT; and PDGFR-b. In the phase 3 TIVO-3 trial, tivozanib improved median progression-free survival (5.6 vs 3.9 months) over sorafenib, leading to FDA approval for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). To our knowledge, there are no published data on the administration of tivozanib via enteral tubes.
Related to this article
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Advertisement
Advertisement